Conference Coverage
-
Conference Coverage
Higher blood pressure after thrombectomy links with bad stroke outcomes
HONOLULU – Observational data showed that ischemic stroke patients with systolic blood pressure above 158 mm Hg after thrombectomy had worse...
-
Conference Coverage
Optical coherence tomography emerging as a promising biomarker for MS
DALLAS – To date, there has been a paucity of studies assessing the effects of DMTs on retinal layer thickness.
-
Conference Coverage
Patient selection for acute stroke thrombectomy stirs controversy
-
Conference Coverage
Study launched to further evaluate the central vein sign in MS
DALLAS – A total of 10 clinical sites in North America are participating, with the Cleveland Clinic coordinating.
-
Conference Coverage
Does BMI affect outcomes after ischemic stroke?
Overweight and obese patients have greater survival and less risk of disability after acute ischemic stroke, according to an analysis of the FAST-...
-
Conference Coverage
Opicapone increased on-time without dyskinesia in patients with Parkinson’s disease
PHILADELPHIA - Improvements of up to 2 hours were seen in an analysis of the BIPARK-1 and BIPARK-2 phase 3 studies.
-
Conference Coverage
Angelman syndrome treatment safe, well-tolerated, and effective in exploratory analyses
PHILADELPHIA – Experimental treatment may benefit adolescents and adults with Angelman syndrome.
-
Conference Coverage
Researchers examine vitamin D, skin pigmentation, and outcomes of pediatric MS
PHILADELPHIA – The association between vitamin D insufficiency and MS outcome in children appears to relate partly...
-
Conference Coverage
Cannabidiol reduces seizures in Dravet syndrome
PHILADELPHIA – Two dosages of the CBD treatment appear to have similar efficacy, but the lower dose may be more...
-
Conference Coverage
Appendectomy linked to increased risk of subsequent Parkinson’s
The findings give pause to the notion of performing discretionary appendectomies in patients who are having surgery for another reason.
-
Conference Coverage
Can an antisense oligonucleotide benefit patients with SOD1-ALS?
PHILADELPHIA – In patients with amyotrophic lateral sclerosis caused by mutations in the SOD1 gene, an investigational treatment reduced SOD1...
-
Conference Coverage
Rimegepant dissolving tablets treat acute migraine in phase 3 trial
PHILADELPHIA – An orally dissolving tablet formulation has significant effects on pain relief and functional ability at 60 minutes post dose.
-
Conference Coverage
Biomarker-based score predicts poor outcomes after acute ischemic stroke
PHILADELPHIA – A free app and online calculator are available to calculate the four-item ‘CoRisk’ score.
-
Conference Coverage
Deutetrabenazine benefit may increase over time in patients with tardive dyskinesia
PHILADELPHIA – Interim results of an open-label study suggest that changes in AIMS score are at least maintained over the course of nearly 3 years...
-
Conference Coverage
MS linked to higher rates of hoarding behavior
SEATTLE – Hoarding and cluttering behavior is more prevelant in the MS population than in the general population.
-
Conference Coverage
Modest evidence for benefit in studies of cannabis in MS
SEATTLE – Trials vary widely in quality, review finds, and most focused on Sativex.
-
Conference Coverage
Adherence to oral treatments for MS is poor
SEATTLE – One in three patients with MS has a lapse in oral therapy that lasts for at least 30 days, and...
-
Conference Coverage
Hazardous cannabis use in MS linked to anxiety, depression
SEATTLE – But it is not clear if there is a cause-and-effect relationship.
-
Conference Coverage
Low baseline heart rate may not increase cardiac risk when starting fingolimod
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.
-
Conference Coverage
Switching from interferon beta-1a to alemtuzumab improves MS outcomes
SEATTLE – The switch is associated with a high rate of freedom from relapse and a reduced rate of brain volume loss...
-
Conference Coverage
Restless legs syndrome in MS linked to cognitive impairment
SEATTLE – Sleep dysfunction could be the key link, study suggests.
-
Conference Coverage
Pediatric MS often goes untreated in the year after diagnosis
SEATTLE – About 65% of patients with pediatric multiple sclerosis do not receive disease-modifying therapy (DMT) within 1 year of diagnosis....
-
Conference Coverage
Balancing privacy, protection in at-risk MS patients
SEATTLE – Keep HIPAA, state laws, and professional guidelines in mind as you consider confidentiality’s limits, an attorney and neuroethics fellow...
-
Conference Coverage
Mutant huntingtin and neurofilament light are potential biomarkers in Huntington’s disease
PHILADELPHIA – The biomarkers successfully distinguish between healthy controls, patients with premanifest disease,...
Latest News
-
From the Journals
Mindfulness yoga reduced stress and motor symptoms in patients with Parkinson’s disease
Yoga was as effective as conventional exercise in improving motor function in patients with Parkinson’s disease.
-
News
Insomnia meds get boxed warning from FDA
Although complex sleep behaviors, such as sleep walking, associated with these medications are rare, the consequences can be deadly.
-
Guidelines
Stroke policy recommendations incorporate advances in endovascular therapy
For stroke patients with a suspected large vessel occlusion, emergency medical services should consider up to 15 minutes of additional travel time...
-
Latest News
FDA approves midazolam nasal spray for seizure clusters
The Food and Drug Administration has approved midazolam (Nayzilam) nasal spray for the acute treatment of intermittent, stereotypic episodes of...
-
News
FDA approves Zolgensma for infantile-onset SMA treatment
Zolgensma is the first gene therapy for the treatment of infantile-onset spinal muscular atrophy in children aged less than 2 years.
-
From the Journals
Coding variants in apolipoprotein B may be associated with early-onset Alzheimer’s disease
The finding may help fill out the genetic risk picture for early-onset Alzheimer’s disease.
-
News from the FDA/CDC
Stewart Tepper: Emgality approval ‘very exciting’
The treatment binds to calcitonin gene-related peptide and is the first therapy to reduce the frequency of episodic cluster headache attacks.
Literature Review
-
Literature Review
Treatment for hepatitis C reduces risk of Parkinson’s disease
Data support the hypothesis that hepatitis C virus infection is a risk factor for incident Parkinson’s disease.